AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Calquence (acalabrutinib) by Quarter
Calquence (acalabrutinib) — Established RoW YoY actual (%) (%)
AstraZeneca Calquence (acalabrutinib): 3.0% in Q2 2026, down 24.0 pts from a year earlier.
Latest, Q2 2026
3.0%
Period ended Jun 30, 2026
Change on a year earlier
-24.0 pts
27.0% in Q2 2025
History
14 quarters
Since Q1 2023
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
“|| Calquence | | 1,022 | | 17 | | 16 | | 687 | | 18 | | 67 | | 36 | | 30 | | 225 | | 13 | | 9 | | 43 | | 3 | | 3”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Calquence (acalabrutinib) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3.0% | -24.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 16.0% | +19.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 48.0% | +39.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 29.0% | +18.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 27.0% | +7.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -3.0% | -47.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 9.0% | -32.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 11.0% | -54.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 20.0% | -35.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 44.0% | -32.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 41.0% | – | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 65.0% | – | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 55.0% | – | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | 76.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Calquence (acalabrutinib) (%), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-erow-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.